Many people managing their weight are exploring new treatment options, and Mounjaro and Wegovy have recently become popular choices. Both medications are prescribed for weight management and are known to aid appetite control and promote healthy weight loss.
In August 2025, Eli Lilly, the manufacturer of Mounjaro, announced a price increase for Mounjaro. This rise means that current users may face higher monthly costs, prompting many to now consider alternatives like Wegovy.
In this article, we explore what Wegovy is, compare it to Mounjaro, explain the recent price changes, and provide a step-by-step guide to switching safely through WePrescribe Online Pharmacy.
What is Wegovy?
Wegovy is a prescription medication containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is designed to help adults with obesity or overweight conditions achieve and maintain weight loss.
Wegovy works by regulating appetite, reducing calorie intake, and promoting a feeling of fullness. It is typically administered via a once-weekly subcutaneous injection. Clinical studies have demonstrated its effectiveness in supporting sustained weight reduction when combined with a balanced diet and regular exercise.
Wegovy vs Mounjaro
When considering a switch, it is important to understand the key differences between Mounjaro and Wegovy. The table below outlines factors users often consider before making the transition:
| Comparison Basis | Mounjaro | Wegovy | User Considerations |
| Active Ingredient | Tirzepatide | Semaglutide | Users may prefer semaglutide due to a longer track record in weight management. |
| Mechanism of Action | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist | Some may find GLP-1-specific treatment better tolerated. |
| Administration | Weekly injection | Weekly injection | Both are convenient. |
| Typical Weight Loss | 15–20% over 68 weeks (variable) | 12–18% over 68 weeks (variable) | Individual response can influence choice. |
| Side Effects | Nausea, diarrhoea, vomiting, mild GI discomfort | Nausea, vomiting, constipation, mild GI discomfort | Side effect profile may determine tolerance and preference. |
| Price (UK) | Approx. £150–£350 per month | Approx. £110–£250 per month | Cost changes may influence the decision to switch. |
| Availability | Prescription required | Prescription required | Switching requires consulting a licensed prescriber. |
Benefits of Switching to Wegovy
Switching to Wegovy can offer several advantages:
- Well-Established Track Record: Wegovy has been widely studied for long-term weight loss, providing confidence in efficacy.
- Tolerability: For some users, semaglutide may cause fewer gastrointestinal side effects compared to Mounjaro.
- Predictable Weight Loss: Clinical trials have shown consistent weekly results when the medication is used as prescribed.
- Support via Online Pharmacy: Platforms like WePrescribe offer structured support for prescription management and dosage guidance.
- Flexibility for Patients: Wegovy provides options for titration and dosage adjustments under medical supervision, enhancing patient safety.
- Wegovy and heart health: Right now, Wegovy is the only weight loss injection proven and licensed to reduce the risk of cardiac health problems, such as strokes and heart attacks, in people with obesity and heart disease. This has been demonstrated in clinical trials.
- Contraception: Wegovy does not interfere with oral contraception, so you can focus on your weight loss journey without changing your contraceptives or worrying about the risk of pregnancy.
Does Switching From Mounjaro to Wegovy Require a Licensed Prescriber?
Yes, switching from Mounjaro to Wegovy does require consultation with a licensed prescriber.
At WePrescribe, we always prioritise patient safety and ensure any change in medication is appropriate for your health profile. Both Mounjaro and Wegovy have different mechanisms of action, dosing schedules, and potential side effects.
A prescriber must review your medical history, current medications, and any underlying conditions before authorising the switch.
Our team are ready to provide guidance on transitioning safely, monitoring for side effects, and adjusting doses if necessary.
Mounjaro September 2025 Price Hike
Eli Lilly, the manufacturer of Mounjaro, announced a price increase effective from September 2025. This rise has been attributed to manufacturing costs, increased demand, and supply chain pressures. The price adjustment in the UK market means patients now face higher monthly costs, making alternative options like Wegovy more attractive.
For many users, switching medications could represent a more predictable and possibly more cost-effective long-term weight management strategy.
Am I Eligible for Wegovy?
Eligibility for Wegovy is determined by medical criteria. In the UK, Wegovy is usually prescribed for adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol.
Can I Switch to Wegovy if My BMI is Under 27?
Switching to Wegovy with a BMI under 27 is generally not recommended because the medication is specifically approved for higher BMI ranges or weight-related health conditions. However, each case is assessed individually by a prescriber. If there are underlying health considerations or previous weight loss challenges, a healthcare professional may determine if Wegovy could be appropriate.
What Are the Doses of Wegovy?
Wegovy dosing follows a stepwise titration schedule:
- Starting Dose: 0.25 mg once weekly for 4 weeks
- Next Dose: 0.5 mg once weekly for 4 weeks
- Intermediate Dose: 1 mg once weekly for 4 weeks
- Target Dose: 1.7mg or 2.4 mg once weekly
The gradual increase helps the body adjust and reduces gastrointestinal side effects. Your prescriber may adjust doses depending on individual tolerance and progress.
Wegovy and Mounjaro Doses
When switching from Mounjaro to Wegovy, it is important to follow a careful dosing conversion to ensure safety and effectiveness. The table below provides a recommended guide for transitioning between medications, helping patients and prescribers determine the appropriate starting dose based on the current Mounjaro regimen. Any final decision with regards to switching would be reviewed and approved by our prescribers.
| Current Mounjaro Dose | Recommended Wegovy Dose | |
| 2.5 mg | 0.25 mg | |
| 5 mg | 0.5 mg | |
| 7.5 mg | 1 mg | |
| 10 mg | 1 mg | |
| 12.5 mg | 1.7 mg | |
| 15 mg | 1.7 mg |
How to Switch from Mounjaro to Wegovy
Switching should always be guided by a healthcare professional. Using WePrescribe Online Pharmacy, the process is simplified:
- Initial Consultation: Schedule an online consultation with a licensed prescriber through WePrescribe. They will review your current Mounjaro dosage, medical history, and weight management goals.
- Assess Eligibility: The prescriber evaluates whether Wegovy is suitable, considering contraindications and potential side effects.
- Washout Period: New guidance has shown that there is only a one-week gap required between your final Mounjaro dose and your first Wegovy dose.
- Prescription Issuance: Once approved, the prescriber issues a Wegovy prescription electronically.
- Delivery and Instructions: WePrescribe delivers the medication to your address with clear usage instructions, including weekly injection guidance.
- Follow-Up Monitoring: The platform schedules follow-ups to track weight loss, monitor side effects, and adjust the dose if required.
WePrescribe Online Pharmacy offers expert guidance and support for patients looking to manage their weight safely and effectively. From assessing eligibility to providing clear instructions for medication use, WePrescribe makes transitioning from Mounjaro to Wegovy simple and secure.
If you are considering making the switch from Mounjaro to Wegovy, get in contact with WePrescribe today to speak with a licensed prescriber and begin your personalised weight management journey.
